title: Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.
abstract: BACKGROUND
  This study investigated the effects of comicronised fenofibrate in patients with dyslipidemia and polymetabolic syndrome X.
  
  
  METHODS
  After a 6-week dietary run-in phase, 37 male patients eligible on lipid criteria entered a 12-week treatment phase consisting of diet plus one capsule daily containing 200 mg of comicronised fenofibrate (Lipanthyl(R)).
  
  
  RESULTS
  A significant reduction in plasma concentrations of total cholesterol, LDL cholesterol and triglyceride was observed after 4, 8 and 12 weeks of treatment with fenofibrate. The improvement in the atherogenic index LDL/HDL cholesterol from a pretreatment 3.8 to 3.0 after treatment was highly statistically significant and may be judged as satisfactory. Significant changes were also observed in haemostatic factors (fibrinogen reduced by 19%, factor VII activity reduced by 18%). Fasting serum insulin levels and insulin response (area under the curve) after oral glucose load were significantly reduced by 26.8% and 18.7%, respectively, indicating an improvement of insulin sensitivity. Systolic and diastolic blood pressure were significantly reduced. Uric acid was significantly reduced by 21.6%.
  
  
  CONCLUSIONS
  These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X.
authors.affiliation: Collegium Medicum Jagiellonian University, Krakow, Poland, Laboratoires Fournier, Daix, France. mmwalus@cyf-kr.edu.pl
authors.forename: B
authors.initials: B
authors.lastname: Idzior-Walus
authors.forename: J
authors.initials: J
authors.lastname: Sieradzki
authors.forename: W
authors.initials: W
authors.lastname: Rostworowski
authors.forename: A
authors.initials: A
authors.lastname: Zdzienicka
authors.forename: E
authors.initials: E
authors.lastname: Kawalec
authors.forename: J
authors.initials: J
authors.lastname: Wójcik
authors.forename: A
authors.initials: A
authors.lastname: Zarnecki
authors.forename: G
authors.initials: G
authors.lastname: Blane
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001786:Blood Glucose; D001794:Blood Pressure / Q000187:drug effects; D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D003402:Creatine Kinase / Q000097:blood; D005215:Fasting; D011345:Fenofibrate / Q000008:administration & dosage*; D005951:Glucose Tolerance Test; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy; D015228:Hypertriglyceridemia / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000097:blood*; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D014527:Uric Acid / Q000097:blood; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D007328:Insulin; D014527:Uric Acid; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D003402:Creatine Kinase; D000469:Alkaline Phosphatase; D011345:Fenofibrate